{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"42","upperLimit":"99","value":"93"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"100","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Defined as achieving donor derived neutrophil count \\>500/uL by day 42 in young children with leukemia or myelodysplastic syndrome undergoing a partially matched single unit umbilical cord blood transplant (UCBT) after a myeloablative preparative regimen consisting of busulfan, melphalan and fludarabine.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients that receive 2 units of umbilical cord blood transplantation (UCBT).","id":"OG000","title":"Double Unit UCB Transplantation"},{"description":"Patients that receive one unit of umbilical cord blood transplantation (only if 2 adequate size and matched units are not available).","id":"OG001","title":"Single Unit UCB Transplantation"},{"description":"Blood and Marrow transplantation","id":"OG002","title":"BM Transplantation"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 42 After Transplant","title":"Incidence of Engraftment","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}